Yesterday, efficacy data from the first novel regimen trial (NC001) were published in the Lancet. The results found that the regimen containing PA-824, moxifloxacin, and pyrazinamide, could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments. Click here to read the full press release.
Tackling TB: Developing the First Novel Drug Regimen from TB Alliance on Vimeo.
Additional TB R&D News:
Eradicate TB Through Public Awareness Campaigns: Educate The Public